Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Unknown 1Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 5Breast 4Other hematologic neoplasm 3Lymphoid 3Plasma cell 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Dermatologic 1CNS 1

Conditions

Vomiting 2Rectal Neoplasms 1Nausea 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Palonosetron × Gastrointestinal × Clear all
NCT03674294 2023-02-08

CINV

Sun Yat-sen University

Phase 3 Completed
248 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Vomiting

NCT00381862 2017-06-12

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

OHSU Knight Cancer Institute

Phase 2 Completed
54 enrolled 7 charts
Gastrointestinal

Colonic Neoplasms, Nausea, Rectal Neoplasms, Vomiting, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡